Evidence map›Paper›PMID 40680482›Full record

ReviewDNA repair2025

Unveiling cGAS mechanisms: Insights into DNA damage and immune sensing in cancer.

Min-Guk Cho, Gaorav P Gupta

Erratum issuedAbstract readReview
In one paragraph

Review in DNA repair, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Min-Guk ChoLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: mingukjo1984@gmail.com.
Gaorav P GuptaLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; UNC MD-PhD Program, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA; Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Curriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: gaorav_gupta@med.unc.edu.

Funding

Tissue Procurement & PathologyP50CA058223 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BENJAMIN CARLISLE CALHOUN · 1992 to 2026
$59.3M
Mre11-Dependent DNA Damage Responses in Breast Cancer PathogenesisR37CA227837 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI GUPTA, GAORAV P. · 2019 to 2025
$2.9M
Defining Optimal Radiotherapy Dose and Fractionation in Combination with Preoperative Immuno-Chemotherapy in Early-Stage Triple Negative Breast CancerR01CA274254 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Dana Casey, Dan Gabriel Duda · 2023 to 2026
$840k
NCI NIH HHS P50 CA058223NCI NIH HHS R01 CA274254NCI NIH HHS R37 CA227837
6 · The paper itself

Abstract

The innate immune sensing system plays a critical role in recognizing and responding to DNA damage, which is a key factor in cancer development and progression. The cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway, in particular, detects cytosolic double-stranded DNA (dsDNA) and activates the innate immune response. Recent studies have shown that cGAS is sequestered on chromatin by binding to the acidic patch (AP) regions of histones. Upon DNA damage, its ability to bind to chromatin-associated dsDNA fragments requires the DNA damage sensor MRE11. Upon its activation, cGAS triggers an innate immune response that can suppress tumorigenesis. However, the context-specific factors that govern whether cGAS engagement leads to effective STING pathway activation remain incompletely defined, particularly in relation to chromatin context, micronuclear integrity, and post-translational modifications. In this review, we explore the dynamic interplay between DNA damage responses and innate immune signaling through the cGAS-STING axis, with a focus on recent mechanistic advances. We further examine how cancers evade or co-opt this pathway and highlight therapeutic opportunities to exploit cGAS-STING signaling for cancer treatment.

Indexed as

DNA DamageImmunity, InnateNeoplasmsNucleotidyltransferasesAnimalsCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseHumansMembrane ProteinsSignal TransductionSTING ProteincGAS protein, humanCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseMembrane ProteinsNucleotidyltransferasesSTING1 protein, humanSTING ProteinAutophagyCancer ProgressionCGAS-STING PathwayDNA DamageDsDNAGenomic instabilityInnate Immune SensingMicronucleusMRE11STING agonist

Identifiers

PMID40680482
PMCPMC12333504

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.